Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2024 financial and operating results and to provide a business update.

Interested parties may access the conference call on May 9 th , 2024, by dialing (800) 715-9871 from the U.S. and Canada and should request the "Lineage Cell Therapeutics Call". A live webcast of the conference call will be available online in the Investors section of Lineage's website. A replay of the webcast will be available on Lineage's website for 30 days and a telephone replay will be available through May 15 th , 2024, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 1330332.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel or "off-the-shelf," cell therapies to address unmet medical needs. Lineage's programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient's functional activity. Lineage's neuroscience focused pipeline currently includes: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed in collaboration with Eterna Therapeutics Inc. For more information, please visit www.lineagecell.com or follow the company on X/Twitter @LineageCell .

Lineage Cell Therapeutics, Inc. IR  
Ioana C. Hone
( ir@lineagecell.com )
(442) 287-8963

LifeSci Advisors  
Daniel Ferry
( daniel@lifesciadvisors.com )
(617) 430-7576

Russo Partners – Media Relations  
Nic Johnson or David Schull
( Nic.johnson@russopartnersllc.com )
( David.schull@russopartnersllc.com )
(212) 845-4242

News Provided by Business Wire via QuoteMedia

LCTX:US
The Conversation (0)
Lineage to Present at 2024 BIO International Convention

Lineage to Present at 2024 BIO International Convention

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company's CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tuesday June 4 th , 2024, at 2:30pm in Theater 3. Company representatives are also hosting meetings with potential partners and collaborators to discuss opportunities for strategic alliances across Lineage's novel pipeline of cell therapy transplant programs. The BIO International Convention is the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world, and is taking place June 3-6, 2024, at the San Diego Convention Center in San Diego, CA.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

  • Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins
  • Clinical Session Expanded to Include Neuralink
  • Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2 nd Annual Spinal Cord Injury Investor Symposium ("2 nd SCIIS"). The 2 nd SCIIS aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived experience, patient and community advocacy organizations, and the investment community, in order to discuss perspectives on current and future treatment alternatives, impact and support SCI disease awareness and clinical trial participation through the implementation of patient appropriate clinical endpoints, and broaden awareness of and investment of capital into SCI.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

  • Established New Services Agreement with Genentech to Support Ongoing Development of the OpRegen ® Program
  • Long-Term Visual Benefits from a Single Administration with OpRegen Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit
  • OpRegen Preclinical Results Presented at 2024 Association for Research in Vision and Ophthalmology Annual Meeting
  • OPC1 Clinical Study Start Up Preparation Underway
  • Received CIRM Grant to Support 2 nd Annual SCI Investor Symposium
  • Appointed Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

"The quarter was highlighted by significant milestones and data updates on our lead program," stated Brian M. Culley, Lineage CEO. "A key area of attention for investors is our partnership with Roche and Genentech, and we are pleased to announce a new services agreement which reflects an additional commitment by Genentech for the benefit of the OpRegen program. We believe this agreement will enable our partners to take advantage of our cell transplant expertise to more fully investigate the promising potential of the OpRegen program and do so in a cost-effective manner. We also are planning to bring our second cell transplant program, OPC1, into the clinic this year for a condition with growing awareness of its unmet need and commercial opportunity. Lastly, we continue to build value through the advancement of our early-stage pipeline, which can help create value by capitalizing on the continued validation of our cell transplant approach."

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
OpRegen®  Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

OpRegen® Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

  • BCVA gains of +5.5 letters at 24 months in Cohort 4 patients (n=10)
  • BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion (n=5)
  • Maintenance or increases in external limiting membrane (ELM) and retinal pigment epithelium (RPE) layers observed by optical coherence tomography (OCT) in patients with extensive bleb coverage of the GA lesion
  • Data suggests OpRegen may counteract RPE cell dysfunction and cell loss in GA by providing support to remaining retinal cells, with effects observed through at least 2 years following a single administration

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month visual acuity results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) of RG6501 ( OpRegen ) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), were presented at the 2024 Retinal Cell & Gene Therapy Innovation Summit . The meeting was jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute . The presentation, "OpRegen ® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 24 Results from the Phase 1/2a Trial," was presented by David Telander, MD, PhD , Retinal Consultants Medical Group, on behalf of Roche and Genentech , a member of the Roche Group.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2024 financial and operating results and to provide a business update.

Interested parties may access the conference call on May 9 th , 2024, by dialing (800) 715-9871 from the U.S. and Canada and should request the "Lineage Cell Therapeutics Call". A live webcast of the conference call will be available online in the Investors section of Lineage's website. A replay of the webcast will be available on Lineage's website for 30 days and a telephone replay will be available through May 15 th , 2024, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 1330332.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Canadian Investment Regulatory Organization Trade Resumption - OM

Canadian Investment Regulatory Organization Trade Resumption - OM

Trading resumes in:

Company: Osisko Metals Incorporated

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Osisko Metals Announces Significant Increase in Mineral Resources at Gaspé Copper

Osisko Metals Announces Significant Increase in Mineral Resources at Gaspé Copper

Osisko Metals Incorporated (the " Company " or " Osisko Metals ") ( TSX-V: OM ; OTCQX: OMZNF ; FRANKFURT: 0B51 ) is pleased to announce an updated Mineral Resource Estimate (" MRE ") for the Gaspé Copper Project, located near Murdochville in the Gaspé Peninsula of Quebec.

The updated MRE (Table 1) includes pit-constrained resources comprising 824 million tonnes grading 0.34% CuEq of Indicated category and 670 million tonnes grading 0.38% CuEq of Inferred category. This MRE represents a 53% increase in copper-equivalent metal content over the previously reported Indicated Resource and a 100-fold increase in copper-equivalent metal content in Inferred Resources (see May 6, 2024 news release and entitled "   2024 Copper Mountain Mineral Resource Estimate   " ).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Silver47 Announces Trading on the TSX-V  and Provides Project Summaries

Silver47 Announces Trading on the TSX-V and Provides Project Summaries

Silver47 Exploration Corp. (TSXV: AGA) ("Silver47" or the "Company), is pleased to announce that its common shares will begin trading on the TSX Venture Exchange (the "TSXV") effective at the open of trading today.

Silver47 wholly-owns three silver and critical metals (polymetallic) exploration projects in Canada and the US: the flagship Red Mountain silver-gold-zinc-copper-lead VMS-SEDEX Project in southcentral Alaska; the Adams Plateau ‎silver-zinc-copper-gold-lead SEDEX-VMS Project in southern British Columbia, and the Michelle ‎silver-lead-zinc-gallium-antimony MVT-SEDEX Project in Yukon Territory.‎

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
FPX Nickel Rock Sampling Program Establishes Mich Property as Compelling Large-Scale Target with Surface Grades Comparable to Flagship Baptiste Nickel Project

FPX Nickel Rock Sampling Program Establishes Mich Property as Compelling Large-Scale Target with Surface Grades Comparable to Flagship Baptiste Nickel Project

 FPX Nickel Corp. (TSXV: FPX) (OTCQB: FPOCF) (" FPX " or the " Company ") is pleased to announce the results of a grid-based rock sampling program at the 100% owned Mich property in the Yukon territory.  This program has both expanded the footprint of known awaruite mineralization and identified new areas of awaruite mineralization beyond the previous claims boundary. Based on the expanded database of Mich rock sampling results, the grade profile of surface rock samples at Mich is now considered comparable with similar samples at FPX's flagship Baptiste Nickel Project (" Baptiste ") in British Columbia .

Highlights

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
RETRANSMISSION: Group Eleven Intersects 8.7m of 23.9% Zn+Pb and 85 g/t Ag; Expands Zinc-Rich Massive Sulphide Zone at Ballywire

RETRANSMISSION: Group Eleven Intersects 8.7m of 23.9% Zn+Pb and 85 g/t Ag; Expands Zinc-Rich Massive Sulphide Zone at Ballywire

Group Eleven Resources Corp. (TSXV: ZNG) (OTC Pink: GRLVF) (FSE: 3GE) ("Group Eleven" or the "Company") is pleased to announce results from latest five step-out holes of the 2024 drill program at the Company's 100%-owned Ballywire zinc-lead-silver discovery ("Ballywire"), PG West Project ("PG West"), Republic of Ireland.

Highlights:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Group Eleven Intersects 8.7m of 23.9% Zn+Pb and 85 g/t Ag; Expands Zinc-Rich Massive Sulphide Zone at Ballywire

Group Eleven Intersects 8.7m of 23.9% Zn+Pb and 85 g/t Ag; Expands Zinc-Rich Massive Sulphide Zone at Ballywire

Group Eleven Resources Corp. (TSXV: ZNG) (OTC Pink: GRLVF) (FSE: 3GE) ("Group Eleven" or the "Company") is pleased to announce results from latest five step-out holes of the 2024 drill program at the Company's 100%-owned Ballywire zinc-lead-silver discovery ("Ballywire"), PG West Project ("PG West"), Republic of Ireland.

Highlights:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×